Describe the prevalence of and burden associated with anemia in patients with CKD, including those who are hyporesponsive to ESA therapy.
|
|
|
|
|
|
Explain the pathophysiologic processes underlying anemia associated with CKD, including potential therapeutic targets
|
|
|
|
|
|